AUS
NZ
UK
CA
USA
IND
Highlights
- Second phase trial completed with no serious adverse events reported
- R327G gel developed for bacterial skin and skin structure infections
- Third phase clinical studies planned in the United States, Australia, and Indonesia
Recce Pharmaceuticals (ASX:RCE) operates within the healthcare and pharmaceutical industry, focusing on treatments that address bacterial skin and skin structure infections. This sector plays an important role in global healthcare, with antibacterial treatments serving as a critical component in managing infections. The market for these treatments is extensive and is expected to experience significant expansion over the next decade.
Second Phase Trial Completion
The dosing phase of the second phase clinical trial for the R327G topical gel has been concluded. During the trial, the gel was applied daily over a course of roughly one to two weeks. Data from the trial reveal that there were no instances of serious adverse events. Subjects experienced either a resolution of infection symptoms or a clear improvement in their condition following the application of the gel.
Regulatory Recognitions
The R327G gel has been incorporated into the United States Food and Drug Administration’s pipeline under the Qualified Infectious Disease Product program established by the GAIN Act. This status offers regulatory advantages designed for treatments in the infectious disease category. In addition, the World Health Organization has listed R327 among antibacterial products for high priority pathogens, underscoring the importance of addressing bacterial resistance on a global scale.
Future Clinical Programs
Full trial data are scheduled for release in the near future. Following the completion of the second phase, the company plans to progress to third phase clinical studies. These studies are set to be conducted across several regions, including the United States, Australia, and Indonesia. In Indonesia, the focus will include studies addressing diabetic foot infections, providing an avenue for further evaluation of the gel’s effectiveness in various clinical scenarios.
Market Opportunity
The area of acute bacterial skin and skin structure infections represents a significant segment within the healthcare market. As the demand for effective antibacterial treatments grows, the scope for addressing a broad range of infections remains extensive. Recce Pharmaceuticals’ focus on the R327G gel aligns with the global effort to address bacterial resistance through innovative therapeutic approaches, offering an important addition to available treatment options in the antibacterial field.
